MILAN, Sept. 15, 2003 (PRIMEZONE) -- BioXell SpA, today announced the appointment of Meenu Chhabra, BSc, MBA as Director of Business Development and Commercial Strategy with immediate effect.
Ms Chhabra most recently worked as Business Development Manager at MCR Research Inc, a Canadian contract research and drug discovery company. During her time at MCR, Ms Chhabra devised and executed business development initiatives as well as marketing programmes, developed and implemented strategic plans for the company and was involved in the strategic turn-around of the drug discovery business.
Prior to joining MCR, Ms Chhabra worked for Fresenius Kabi Healthcare as a Business Development Manager, obtained an MBA from York University with specialisation in Marketing and Strategic Management in 2001 and her undergraduate degree from the University of Toronto in Neuropharmacology and Toxicology in 1995.
Alex Martin, Chief Business Officer said, "We are delighted to have Meenu join us at BioXell and for her to provide key input in both the business development side of the company as well as the commercial strategy. Her experience and insights will be invaluable to BioXell."
Ms Chhabra added, "I am very much looking forward to being part of such an entrepreneurial and dynamic company and contributing to its on-going success."
BioXell is a private biopharmaceutical company focused in the areas of inflammatory disease and urology disorders with offices in Milan, Italy, and Nutley, NJ, USA. Through its two proprietary technology platforms based on Vitamin D3 analogues and TREM receptor biology, BioXell has identified a number of promising lead development programmes. Its pipeline includes a promising compound, BXL-628 for benign prostatic hyperplasia (currently in Ph II trials) as well as research programmes in transplantation, diabetes, and sepsis as well as other urological indications. BioXell has a collaboration with TaiGen Biotechnology (Taiwan) for the research and development of small molecules active against GPCRs in the area of inflammatory diseases. To date, BioXell has raised over 39 million through the participation of world-class VC investors including MPM Capital, NIB Capital Private Equity, Index Ventures and Life Sciences Partners. BioXell currently employs 44 people. More information on BioXell can be found on: www.bioxell.com
Please click on the link to view the full press release: http://reports.huginonline.com/917184/123019.pdf